US High Growth Tech Stocks to Watch

In This Article:

The United States market has experienced a notable upswing, rising 7.1% over the last week and climbing 7.7% in the past year, with earnings forecasted to grow by 14% annually. In this context of growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to evolving market trends.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.27%

29.79%

★★★★★★

Alkami Technology

20.46%

85.16%

★★★★★★

Travere Therapeutics

28.65%

66.06%

★★★★★★

TG Therapeutics

26.06%

37.39%

★★★★★★

Arcutis Biotherapeutics

26.11%

58.46%

★★★★★★

Clene

62.08%

64.01%

★★★★★★

Alnylam Pharmaceuticals

23.08%

58.85%

★★★★★★

AVITA Medical

27.81%

55.17%

★★★★★★

Lumentum Holdings

21.34%

120.49%

★★★★★★

Ascendis Pharma

32.75%

59.64%

★★★★★★

Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Exact Sciences

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Exact Sciences Corporation develops and markets cancer screening and diagnostic test products globally, with a market cap of approximately $8.44 billion.

Operations: The company generates revenue primarily from its biotechnology segment, totaling approximately $2.76 billion. Its focus on cancer screening and diagnostic tests positions it within the healthcare sector, targeting both domestic and international markets.

Exact Sciences is making significant strides in the high-growth tech sector, particularly with its recent advancements in cancer diagnostics. The launch of Oncodetect, a test for detecting molecular residual disease across multiple solid tumors, showcases their commitment to innovation; this test enhances treatment decisions and monitoring with its ability to detect one ctDNA molecule among 20,000 cfDNA molecules. With an R&D expense ratio that has consistently been above industry average at 15% of revenue, Exact Sciences is not just expanding its product line but also ensuring these innovations reach a broad audience through strategic Medicare collaborations and robust clinical validations like the Alpha-CORRECT study. This approach not only secures their position in precision medicine but also aligns with broader healthcare trends towards personalized care solutions.

NasdaqCM:EXAS Revenue and Expenses Breakdown as at Apr 2025
NasdaqCM:EXAS Revenue and Expenses Breakdown as at Apr 2025

DigitalOcean Holdings

Simply Wall St Growth Rating: ★★★★☆☆